


1 SUPPLEMENTARY FIGURES



2
3 **Figure S1 FMRP is phosphorylated at S499 upon neuronal depolarization. Related to Figure**

4 **1.**

5 (A) Representative western blots of global post-translational modifications upon neuronal
6 depolarization ($n = 3$ each condition). Western blots are quantified by ImageJ. Relative
7 intensities of different proteins are quantified by normalizing to GAPDH.

8 (B) Phos-tag gels assaying YTHDF1 phosphorylation in the mouse brain after fear
9 conditioning (FC) or electroconvulsive treatment (ECT).

10 (C) Phos-tag gel analyzing YTHDF1 in cultured mouse neurons after KCl depolarization.

11 (D) Scatter plot characterizing the reproducibility between the two replicates for identifying
12 YTHDF1 protein partners using mass spectrometry.

13 (E) Scatter plot showing the intensity of individual protein identified in fractions co-
14 immunoprecipitated with YTHDF1.

15 (F) Schematics showing the experimental setup for the reporter assay to study YTHDF1-
16 mediated translation in HEK293T cells transfected with siControl siRNA. The N terminus
17 of YTHDF1 was tethered to the reporter firefly luciferase RNA by MCP-MS2 interactions.
18 Bar plot showing that YTHDF1 tethering in WT HEK293T cells does not alter target RNA
19 translation.


20 (G) qPCR results validating individual knockdown of candidate proteins that negatively
21 regulates m⁶A-mediated translation. Individual RNA level was normalized to *HPRT1*.

22 (H) Bar plot showing that *FMR1* knockdown did not alter the translation efficiency of
23 untethered reporter firefly luciferase or renilla luciferase coding sequences.

24 (I) Western blots showing response of FMRP phosphorylation to different small molecules in
25 cultured neurons. DMSO was used as a control and cellular extracts were prepared at 5
26 minutes after application of drugs. FMRP phosphorylation levels were obtained by
27 normalizing band intensity of p-FMRP to band intensity of t-FMRP. The final
28 concentrations of individual small molecules were determined based on their reported IC₅₀
29 values against their physiological targets (NPS 2390: 82 nM, DHPG, 7 μM, and TTX, 2
30 nM).

31 (J) Western blotting of mouse hippocampal neurons validating knockout of *Fmr1* gene.

32 Data are mean ± s.e.m. (A), (F), (G), (H) and (I), statistical analysis was performed using unpaired
33 two-tailed *t*-test with Welch's correction. Exact *P* values are indicated, and NS denotes *P* values >
34 0.05.



35

36 **Figure S2 FMRP and its phosphorylation regulates YTHDF1 condensing. Related to Figure**

37 **2.**

38 (A) Left: illustration of phosphorylation inhibitor treatment. Right: western blot of FMRP S499

39 phosphorylation in HeLa cells treated by CX-4945.

40 (B) qPCR results showing knockdown efficiency of *FMR1* RNA in HeLa cells.

41 (C) Western blots of insoluble fractions isolated from HeLa lysates. YTHDF1 and RPS6 were

42 both enriched after *FMR1* knockdown.

43 (D) Western blots characterizing phosphorylated recombinant FMRP with CK2 *in vitro*.

44 Unphosphorylated FMRP was recombinantly purified from BL21(DE3). Phosphorylation

45 reaction was performed with recombinant casein kinase 2 enzyme.

46 (E) Western blots showing YTHDF1-FMRP associations. Immunoprecipitations were


47 performed with FMRP antibody in HeLa cells overexpressing WT or phosphor-null mutant

48 (S499A) of FMRP.

49 (F) Proximity ligation assay quantifying interactions between YTHDF1/FMRP or

50 YTHDF1/RPS6.

51 Data are mean \pm s.e.m. (B), statistical analysis was performed using unpaired two-tailed *t*-test
52 with Welch's correction. (F), statistical analysis was performed with Wilcoxon rank sum test. Exact
53 *P* values are indicated, and NS denotes *P* values > 0.05.



54

55 **Figure S3 RNase treatment precipitates condensates containing YTHDF1 and ribosomal**56 **proteins. Related to Figure 3.**

57 (A) Top: representative images of the turbidity of HEK293T lysates treated by RNase and high
58 salt (NaCl) or 1,6-hexanediol (1,6-HD). Bottom: turbidity measured by OD 600 nm from
59 nanodrop.

60 (B) Analysis of proteins precipitated by RNase treatment. Top left: illustration of experimental
61 design. Bottom left: representative images of the RNase-induced granulation formation.
62 Right: silver stain of proteins present in the condensed phase in response to RNase
63 treatment.


64 (C) Distribution of YTHDF1, FMRP and RPS6 in the condensed phase in response to RNase
65 treatment. Quantifications of western blots were performed by normalizing intensities of
66 each band to that of “Input RNase –” lane of each protein assayed.

67 (D) Gene ontology terms enriched by condensation-dependent YTHDF1 protein partners. GO
68 enrichment was done with ClusterProfiler algorithm built in R.

69 (E) Western blots showing expression of different YTHDF1 mutants in HeLa cells and their
70 interactions with FMRP.

71 (F) Relative distribution of *YTHDF1* in polysome fractions. *YTHDF1* percentage in the
72 ribosomal fractions was quantified by normalizing intensity of YTHDF1 in 40S, 60S and
73 80S ribosome to total intensity. 1,6-hexanediol was added at 2% (w/v) concentration.

74 Data are mean \pm s.e.m. (C), statistical analysis was performed using unpaired two-tailed *t*-test
75 with Welch's correction. Exact *P* values are indicated, and NS denotes *P* values > 0.05.



76

77 **Figure S4 SAC selectively inhibits YTHDF1 at low concentrations. Related to Figure 4.**

78 (A) IC_{50} of m^6A -containing mRNA (m^6A) to compete with YTHDF1-target binding as measured
 79 by AlphaScreen experiments. Different concentrations of unlabeled m^6A -containing
 80 mRNA were added to compete with fluorescence molecule for YTHDF1 as indicated.

81 (B) Z' scores to characterize the stability of small molecule inhibitor screening assay. The
 82 experiment conditions (NCC and Gain) were repeated 40 times as indicated. Z' was
 83 calculated based on the values of mP .


84 (C) ITC analysis between SAC and YTHDF1 at 25 °C. 1 mM SAC was titrated into 50 μM
 85 YTHDF1.

86 (D) The binding curve of SAC and YTHDF1 obtained via MST assay.

87 (E) RNA levels of YTHDF2 target (*PRR5L*) upon gradient SAC treatments by a concentration
 88 gradient. *PRR5L* expressions were quantified by normalizing RNA levels to *GAPDH*.

89 (F) Top: western blots showing the protein levels of YTHDF1 targets (eEF1G and LRPAP1)
 90 upon SAC treatments by a concentration gradient. Bottom: protein levels relative to
 91 GAPDH quantified by ImageJ ($n = 3$).

- 92 Data are mean \pm s.e.m. Statistical analysis was performed using unpaired two-tailed *t*-test with
- 93 Welch's correction. Exact *P* values are indicated, and NS denotes *P* values > 0.05 .



94

95 **Figure S5 YTHDF1 and YTHDF2 differ in their N-terminal intrinsically disordered domain**
 96 **sequence and exhibit different fiber formation behaviors. Related to Figure 5.**


97 (A) Prion-like score of YTHDF1 and YTHDF2 predicted by PLAAC.

98 (B) Thioflavin T (ThT) assay of YTHDF1 and YTHDF2 low-complexity domains. Freshly
 99 purified proteins were incubated for 100 hours in native buffer.

100 (C) Trinucleotide periodicity of P-sites identified with ribosome-protected fragments in
101 individual samples showing data quality of riboLace-seq.

102 (D) Scatter plots showing both ribosome-protected fragments (RPF) and input RNA level
103 (input) obtained by riboLace-seq. Data for WT and *Fmr1* KO neurons were shown.

104 (E) Dot plots showing the gene ontology terms enriched for hyper-translated (left) or hypo-
105 translated (right) genes upon SAC treatment. Top biological process terms enriched were
106 shown.



107

108 **Figure S6 RiboLace measures translation events in organoid models. Related to Figure 6.**

109 (A) Trinucleotide periodicity of P-sites identified with ribosome-protected fragments in
 110 individual samples indicating the good data quality of RiboLace-seq.

111 (B) Scatter plots showing the changes in RNA translation in forebrain organoids upon SAC
 112 treatment.

113 (C) Gene ontology terms enriched by hypo-translated genes in FXS organoids upon SAC
114 treatment.

115 (D) Representative images and quantification showing the synaptic density in FXS or control
116 (CTRL) organoids. Knockdown of *YTHDF1* or SAC treatment was performed. The
117 synaptic density was calculated the number of SYNAPSIN I positive puncta per 100 μm^2
118 MAP2 (microtubule associated protein 2) positive area. Data are presented as mean \pm s.d
119 (n = 10 sections from at least from 2-3 organoids each condition). Statistical analysis was
120 performed using two-way ANOVA. Scale bars: 50 μm .